Company intelligence / Profile preview
Exscientia
Oxford, Oxfordshire, UKfind-and-update.company-information.service.gov.uk ↗
- Ownership
- Public · EXAI
- Employees
- ~450
- Development stage
- Phase 1
01
Overview
Exscientia has pioneered the use of artificial intelligence to automate small molecule drug design. It was the first company to bring an AI-designed molecule into clinical trials. Its lead asset ('4318) targeting PKC-theta entered Phase I trials via partnership with Bristol Myers Squibb and showed positive early results by May 2024. Another wholly owned program targeting MALT1 protease expects CTA submission in late 2024. The company claims up to a tenfold increase in productivity over traditional methods and has more than two dozen projects advancing internally or through partners across oncology, immunology, hematology, and other areas.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesBispecific drugs and polypharmacology approaches
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Sanofi (strategic research collaboration on cancer/immunology)Merck & Co.Bristol Myers Squibb ('4318 program)GT Apeiron (CDK7 inhibitor acquisition)
04
Financials
- Market cap
- $633.2M
- Total revenue
- $4.9M
- Enterprise value
- $407.7M
Beyond the preview
Go deeper on Exscientia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exscientia.